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The adaptive immune response to viral vectors reduces 
vector-mediated transgene expression from the brain. It is 
unknown, however, whether this loss is caused by func-
tional downregulation of transgene expression or death 
of transduced cells. Herein, we demonstrate that dur-
ing the elimination of transgene expression, the brain 
becomes infiltrated with CD4+ and CD8+ T cells and that 
these T cells are necessary for transgene elimination. Fur-
ther, the loss of transgene-expressing brain cells fails to 
occur in the absence of IFNγ, perforin, and TNFα recep-
tor. Two  methods to induce severe immune suppression in 
immunized animals also fail to restitute transgene expres-
sion, demonstrating the irreversibility of this process. The 
need for cytotoxic molecules and the irreversibility of the 
reduction in transgene expression suggested to us that 
elimination of transduced cells is responsible for the loss 
of transgene expression. A new experimental paradigm 
that discriminates between downregulation of transgene 
expression and the elimination of transduced cells demon-
strates that transduced cells are lost from the brain upon 
the induction of a specific antiviral immune response. 
We conclude that the anti-adenoviral immune response 
reduces transgene expression in the brain through loss of 
transduced cells.
Received 28 June 2011; accepted 13 October 2011; published online  
10 January 2012. doi:10.1038/mt.2011.243
IntroductIon
Immune responses against adenoviral vectors challenge the use of 
such vectors for gene therapy of the brain. Transgene expression in 
the absence of an antiadenoviral immune response has been shown 
to last up to 12 months.1,2 However, once a systemic antiadenoviral 
immune response is induced, transgene expression is eliminated 
from the brain within 30–60 days.3 The cellular and molecular 
mechanisms by which the immune response eliminates transgene 
expression from the central nervous system (CNS) remain poorly 
understood. Given the clinical use of first-generation adenoviral 
vectors for gene therapy of brain diseases,4–12 understanding the 
cellular and molecular basis of brain immune responses as well 
as their consequence for brain structure and function are critical 
elements of clinical gene therapy in neurology using viral vectors.
Especially, whether the immune response blocks transgene 
expression or actually kills transduced cells needs to be deter-
mined, as only functional inhibition of transgene expression 
would be transient and reversible. Immune-mediated killing of 
infected brain cells would represent an unacceptable consequence 
and potentially limit clinical gene therapy.13–15
Recently, we demonstrated that upon the systemic 
 immunization against adenovirus, antiviral CD8+ T cells form 
close anatomical appositions, i.e., immunological synapses, with 
target adenovirally transduced astrocytes.16,17 During this process, 
transgene expression is lost from ~50% of infected cells, 85% of 
which are reactive astrocytes.18 Additionally, T-cell activation leads 
to the production and secretion of IFNγ, perforin, and TNFα.19–21
Much research has also been done on the mechanisms by 
which the immune system clears infection from the brains of 
animals infected with Lymphocytic Choriomeningitis Virus 
(LCMV),22 Sindbis Virus,23 measles virus, West Nile virus,24 
Borna virus,25 Murine Cytomegalovirus,26 Theiler’s Virus, Semliki 
Forest virus, mouse hepatitis virus (MHV),27 or herpes simplex 
virus type 1 (HSV1).28 Cytotoxic T cells, especially CD8+ T cells, 
IFNγ, perforin, and TNFα have all been shown to be necessary 
to various degrees to clear or control viral infections in the brain. 
However, bona fide killing of infected brain cells has only ever 
been demonstrated using in vitro paradigms, but never in vivo.29 
Correspondence: Pedro R Lowenstein, Departments of Neurosurgery, and Cell and Developmental Biology, 4570 MSRB-II, 1150 West Medical Drive, 
University of Michigan School of Medicine, Ann Arbor, MI, 48109-0650, USA. E-mail: pedrol@umich.edu
Immune-mediated Loss of Transgene Expression 
From Virally Transduced Brain Cells Is Irreversible, 
Mediated by IFNγ, Perforin, and TNFα, and due to 
the Elimination of Transduced Cells
Jeffrey M Zirger1–3, Mariana Puntel1–3, Josee Bergeron1–3, Mia Wibowo1–3, Rameen Moridzadeh1–3, 
Niyati Bondale1–3, Carlos Barcia1–3, Kurt M Kroeger1–3,*, Chunyan Liu1–3, Maria G Castro1–5  
and Pedro R Lowenstein1–5
1Board of Governors’ Gene Therapeutics Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; 2Department of Medicine,  
David Geffen School of Medicine at UCLA, Los Angeles, California, USA; 3Department of Molecular and Medical Pharmacology, David Geffen School  
of Medicine at UCLA, Los Angeles, California, USA; 4Current  address: Department of Neurosurgery, The University of Michigan, Medical School, Ann 
Arbor, Michigan, USA; 5Current address: Department of Cell and Developmental Biology, The University of Michigan, Medical School, Ann Arbor,  
Michigan, USA; *Deceased
Molecular Therapy  vol. 20 no. 4 apr. 2012 809
© The American Society of Gene & Cell Therapy
Immune-mediated Elimination of Virally Infected Brain Cells
It is thought that clearing of virus from the brain occurs without 
physical  damage to the structure of the CNS.30
We now describe results using a novel reporter system to 
discriminate whether immune responses to adenoviral vec-
tors are functional and reversible or cytotoxic. ROSA26 trans-
genic mice that encode within the ROSA locus a STOP sequence 
flanked with loxP sites upstream of the transcriptional start site 
of the lacZ gene. In this mouse strain, genomic β-galactosidase is 
only expressed after Cre-mediated excision of loxP-flanked STOP 
sequence.31 We used an adenoviral vector–expressing Cre recombi-
nase to infect the brains of ROSA26 mice.32 Upon systemic immu-
nization, functional downregulation of Ad-mediated transgene 
expression should result in loss of Cre expression, without loss of 
genomic β-galactosidase expression; loss of both Cre—expressed 
from the adenoviral  vector—and β-galactosidase—expressed 
from the genome of infected cells—would be the result of killing 
of Ad-infected brain cells.30
Previous studies have shown that adeno-associated virus 
(AAV) and lentiviral vector–mediated expression of Cre in  neurons 
of ROSA26 transgenic mice induce long-term expression of 
β-galactosidase from the recombined ROSA26 locus,33 thereby 
supporting the feasibility of our reporter system. In the liver, 
Wang et al.34 have used AAV-Cre to demonstrate that instability 
of newly formed AAV dsDNA is responsible for low rAAV trans-
duction efficacy. These authors observed that upon administra-
tion of AAV-expressing Cre recombinase to ROSA26 transgenic 
mice, liver expression of recombined lacZ remains high and stable, 
while expression of AAV-encoded alkaline phosphatase is modest; 
although dsAAV are formed in most infected cells, they are rapidly 
lost. The instability of a large proportion of AAV dsDNA precludes 
their use in our paradigm which requires continued, comparable, 
stable, and long-term expression of genomic recombined lacZ and 
transgenes encoded by episomally-located Ad vectors’ genomes.
Our results indicate that, upon systemic antiadenoviral immu-
nization, CD8+ and CD4+ T cells, IFNγ, perforin, and TNFα are all 
necessary to reduce transgene expression from the brain. In addi-
tion, immune suppression fails to restitute transgene expression. 
Finally, both expression of Cre and β-galactosidase were reduced 
by >80% in our ROSA26 paradigm. We conclude that transgene 
expression from adenoviral vectors in the brain is eliminated by 
the killing of virally infected brain cells.
results
Immune cells infiltrate the brains of Ad-transduced 
mice, establish contacts with transduced brain cells, 
and reduce transgene expression for up to 120 days
We examined the immune cell types infiltrating the brain paren-
chyma during the elimination of Ad-mediated transgene expres-
sion from the brain. Naive C57Bl/6 mice were injected in the right 
brain striatum with first-generation adenoviral vectors encoding 
herpes simplex type 1 thymidine kinase (Ad-TK) as a marker trans-
gene. Thirty days later, animals were immunized systemically with 
a first-generation adenoviral vector encoding an unrelated trans-
gene (Ad-HPRT) (Figure 1a). Expression of TK is reduced follow-
ing immunization, remaining at very low levels for up to 120 days 
after immunization (Figure 1b). Figure 1b (%) and Figure 1c (total 
numbers) indicate that CD4+ T cells infiltrate the brain as early as 
7 days post immunization and remain in the brain at significant lev-
els up to 120 days after immunization. CD45+ cells, a marker repre-
senting all bone marrow–derived cells, infiltrate the mouse brain as 
early as 14 days post immunization, with peak levels obtained at 60 
days after immunization and remain in the brain at significant levels 
up to 90 days post-immunization; at early time points, when CD4+ 
cell counts are high, the comparable numbers of CD45+ cell num-
bers obtained are most likely reflecting the influx of T cells; how-
ever, from 30 days onwards, as T-cell numbers decrease, CD45+ 
cells most likely indicate the presence of macrophages/microglia 
in the brain; to avoid any confusion in later experiments to detect 
intercellular interactions, we used the antibody F4/80 to label only 
macrophages/microglia. CD8+ T cells infiltrate the mouse brain 
later, with peak levels obtained at 90 days after immunization. 
To determine the cell type  transduced, brain sections were double 
labeled with antibodies to the  transgene HSV1-TK, and the neu-
ronal nuclear marker (NeuN) or the astrocyte marker glial fibrillary 
acidic protein (GFAP; Figure 1d). More than 80% of transduced 
cells were neurons, while ~12% were astrocytes. The remaining 
cells were not characterized in detail. Analysis of in vivo cytotoxic 
T lymphocyte activity reveals that systemic immunization with 
Ad-HPRT generates systemic circulating cytotoxic T lymphocytes 
specific and cytotoxic for  target cells presenting adenovirus epitopes 
(Figure 1e,f).
Confocal microscopy was used to quantitate the existence of 
close anatomical contacts between Ad-transduced cells and either 
CD4+ T cells (Figure 2a,b), CD8+ T cells (Figure 2 c,d), or F4/80+ 
macrophages/activated microglia (Figure 2 e,f). The detailed 
kinetics of immune cell contacts with transduced TK-expressing 
brain cells is shown in Figure 2g,h,i. Infiltrating T cells were not 
detected in nonimmunized animals (data not shown).
Figure 2g (percentage of immune cells contacting target cells) 
indicates that a maximum of 10% of CD4+ T cells contacts  target 
cells, while >30% of CD8+ T cells or F4/80 macrophages/microglia 
do so; Figure 2h (percentage of transduced cells being contacted 
by immune cells) indicates that while only 8% of target cells are 
directly contacted by CD4+ T cells, 20% are contacted by CD8+ 
T cells, but almost 75% of target cells are in close  anatomical con-
tact with macrophages/activated microglia cells; Figure 2i (number 
of immune cells per target transduced cells) indicates that while 
1–1.5 T cells contact target cells, 2 contacts of F4/80 microglia/mac-
rophages per transduced cell were detected; these data suggest an 
important role for F4/80+ macrophages/activated microglia in the 
reduction of Ad-mediated transgene expression from the mouse 
brain, especially as phagocytosis of transduced cells was detected 
(Figure 3 a–f).
the adaptive immune response cd4+ and cd8+ 
t cells, and IFnγ, perforin, and tnFα, are all necessary 
for the elimination of transgene-expressing brain 
cells: results from knockout  experimental models
Transgene loss was absent in Rag1 knockout mice, which lack T 
and B cells, and mice lacking CD8+ T cells (Figure 4a). In CD4+ 
T cell knockout animals, transgene expression was increased, with 
respect to controls. These data indicate that both CD8+ T cells and 
CD4+ T cells play a role in the elimination of transduced cells, 
with CD4+ T cells playing the most prominent role.
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Figure 1 elimination of Ad-mediated transgene expression occurs concomitantly with a biphasic influx of anti-adenovirus-specific immune cells 
into the mouse brain. (a) Experimental design. C57BL/6 mice were injected with Ad-TK into the striatum. Thirty days later, mice were immunized i.p. 
with Ad-HPRT, or saline as a control (nonimmunized). Mice were euthanized at 7, 14, 30, 60, 90, and 120 days post immunization. Brain sections were 
assessed by immunohistochemistry with antibodies specific for TK, CD4+ T cells, CD8+ T cells, and CD45+ cells. The number of immunoreactive cells was 
quantified by quantitative stereology at each time point. (b) The dynamics of immune cell influx into the brain are shown as percentages of the maximum 
value of each immune cell population over time. The percentage of cells expressing TK in immunized and nonimmunized mice is also shown. (c) The total 
number of immune cells in the brain is shown at each time point; *P < 0.05 compared to all other time points, two-way ANOVA followed by Tukey’s test. 
(d) Brain sections from immunized mice were double labeled with antibodies specific for TK (transgene expression, green) and neurons (red, NeuN), or 
astrocytes (magenta, GFAP). Immunofluorescence was analyzed by confocal microscopy colocalization of transgene expression and neurons or astrocytes. 
The percentage of double labeled cells is shown. (e) Experimental design of in vivo cytotoxic T lymphocyte assay is shown. 14 and 7 days before adoptive 
transfer, C57BL/6 mice were immunized with Ad-HPRT, or saline as a control (i.p.). Before adoptive transfer, splenocytes were labeled with either 2 μM 
CFSE (CFSEhi) or with 0.2 μM CFSE (CFSElo). CFSEhi splenocytes were also pulsed with adenovirus fiber peptide and heat-inactivated Ad-HPRT. A 1:1 mix-
ture of each cell population was adoptively transferred into immunized mice. 18 hours later, animals were euthanized and splenocytes were assessed for 
CFSE fluorescence by flow cytometry. (f) The ratio of CFSEhi:CFSElo splenocytes is shown. A reduction in the population of CFSEhi indicates antigen-specific 
in vivo cytotoxic T lymphocyte activity.
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Stereological quantification of TK transgene expression in immu-
nized mice lacking perforin and TNFα receptor expression revealed 
no transgene loss at 30 days after immunization; however, at 60 and 90 
days after immunization, loss of transgene-expressing cells was seen 
in both knockout animal strains (Figure 4b). Stereological quantifica-
tion of TK transgene expression in immunized IFNγ knockout mice 
revealed an inhibition of transgene loss at all time points studied. 
These data suggest that perforin and TNFα play a role in the early (30 
days) phase of transgene elimination, while IFNγ is necessary at all 
time points examined (Figure b). All mice, except for Rag1(−/−) which 
lack T and B cells, showed increases in adenovirus-neutralizing titers 
(1:8 to 1:128; data not shown) following systemic immunization.
loss of transgene expression is irreversible
To assess whether the constant presence of immune cells is required 
to suppress Ad-mediated transgene expression in the mouse 
brain, we assessed transgene expression in the brains of immu-
nized animals following immunosupression by either  irradiation 
(Figure 5a–e) or treatment with rapamycin (Figure 6a–c). 
Following irradiation, TK expression did not increase (Figure 5a). 
Immunohistochemistry analysis of CD4+ T cells in the brains 
(Figure 5b) or flow cytometry analysis of CD4+ T cells and CD8+ 
T cells in the spleens (Figure 5c–d) confirms that irradiation dra-
matically reduces the levels of immune cells. Irradiation also caused 
a sharp reduction in the frequency of adenovirus-specific IFNγ-
secreting T lymphocyte precursors in the mouse spleen (Figure 5e). 
The decrease in T-cell function was less following treatment with 
rapamycin, but TK expression did not recover back to control 
levels (Figure 6a–c). These results demonstrate that the constant 
presence of T cells is not required to suppress Ad-mediated trans-
gene expression from the brain, thus suggesting that elimination of 
transgene expression is irreversible. The irreversibility of the loss of 
TK transgene expression following immune suppression strongly 
suggests the elimination of transduced cells from the brain.
elimination of Ad-mediated transgene expression 
occurs mainly through the loss of transduced cells
We next tested the hypothesis that elimination of transgene expres-
sion results from the elimination of transduced cells, rather than 
inhibition of vector-encoded transgene expression. To do so, we 
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Figure 2 Quantitative analysis of the interactions between Ad-transduced brain cells and cd4+ and cd8+ t cells and macrophages. Representative 
confocal images of brain sections from immunized mice depicting close anatomical contacts between (a,b) CD4+ T cells (CD4+, red) and Ad-infected cells 
(TK, green), (c,d) CD8+ T cells (CD8+, red) and Ad-infected cells (TK, green), (e,f) macrophages/activated microglia (F4/80, red) and Ad-infected cells 
(TK, green). In all images, nuclei are stained with DAPI (blue). Stereological quantification of CD4+ T cells, CD8+ T cells, and macrophages over time in 
the brains of Ad-immunized animals depicting (g) the percentage of each immune cell contacting TK-expressing cells, (h) the percentage of TK cells with 
immune cell contacts, and (i) the number of immune cell contacts per TK-expressing cell. TK, thymidine kinase; DAPI, 4’,6-diamidino-2-phenylindole.
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developed a novel method in ROSA26 mice. A  first-generation 
Ad-vector expressing Cre  recombinase (Ad-CAG-Cre) was injected 
into the brains of transgenic ROSA26 mice (B6;129Gt(ROSA) 
26Sortm1/Sho/J). ROSA26 mice harbor a genomic lacZ gene with a 
STOP sequence flanked by loxP sites upstream of the lacZ start 
codon. This STOP sequence prevents translation of the lacZ 
gene. Cre recombinase expression (provided in trans by Ad-CAG-
Cre) excises the STOP sequence, thus allowing constitutive and 
permanent β-galactosidase expression from the genome of trans-
duced cells, while expression of Cre recombinase can be used to 
monitor transgene expression from the viral vector (Figure 7a). 
Upon immunization, changes in the expression of Cre recombinase 
(vector genome) will indicate changes in the expression from the 
viral vector; changes in the expression of β-galactosidase (ROSA26 
genome) will indicate changes in the number of transduced cells. 
In this experimental paradigm, following antiadenoviral immu-
nization, a purely functional inhibition of transgene expression 
will show a reduction of Cre recombinase, but no reduction in the 
level of β-galactosidase; a reduction in the expression of both Cre 
 recombinase and β-galactosidase immunoreactive cells will indicate 
the loss of transduced cells, i.e., cell death.
F4/80+ cells phagocytose brain cells transduced with Ad-TK or Ad-β-gal
Figure 3 F4/80+ cells phagocytose brain cells transduced with 
Ad-tK or Ad-β-gal. (a–b) Confocal microscopy analysis of immu-
nized animals reveal macrophages (F4/80, red) which have phagocy-
tosed an Ad-infected cell (TK, green). (a) A cell that displays strong 
TK immunoreactivity (green) surrounded by F4/80-immunoreactive 
processes from macrophages/microglia (red). (b) A final stage in 
which amorphous transgene immunoreactivity is still detected within 
F4/80-immunoreactive macrophages/microglia. Green arrows indicate 
transgene immunoreactivity and red arrows indicate the processes of 
F4/80-immunoreactive macrophages/microglia. (c–f) Confocal micros-
copy analysis of immunized animals in essentially identical experiments, 
but injected in the brain with a first-generation adenovirus expressing 
the transgene β-galactosidase—instead of herpes simplex virus type I 
thymidine kinase—reveals macrophages (F4/80, red) which have phago-
cytosed an Ad-infected cell (β-galactosidase, green). Note that F4/80 
immunoreactive processes enclose various amounts of β-galactosidase, 
originally contained within the transduced brain cells. For all images, 
notice that the side views across the confocal stacks reveals that the 
transgene-immunoreactive material is indeed within macrophages, i.e., 
it is completely surrounded by F4/80 immunoreactive processes. Notice 
that macrophages are able to phagocytose adenoviral transduced cells 
independently of the transgene expressed by the viral vectors.
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Figure 4 cd4+ and cd8+ t cells are required for elimination of 
Ad-mediated transgene expression from immunized mice; tnFα 
and perforin are required in the early stages and IFnγ is required 
throughout elimination of transgene expression. Wildtype C57BL/6 
mice, or CD4−/−, CD8−/−, Rag1−/−, Prf−/−, Tnfrsf1α(−/−), or IFNγ−/− immune 
knockout mice were injected with Ad-TK into the striatum. Thirty days 
later, mice were immunized with Ad-HPRT, or saline as a control (i.p.). 
Mice were euthanized at 30, 60, and 90 days post immunization. Brain 
sections were assessed by immunohistochemistry with an antibody spe-
cific for TK. The number of immunoreactive cells was quantified by ste-
reology at each time point. (a) The dynamics of TK immunoreactivity in 
the brains of transgenic immune cell knockout mouse strains, i.e., CD4−/−, 
CD8−/−, Rag1−/−, which are displayed as the relationship of TK immuno-
reactive cells at each time point with respect to their levels at the day 
of immunization; *P < 0.05 compared to all other time points, one-way 
ANOVA followed by Tukey’s test. (b) The dynamics of TK immunoreac-
tivity in the brains of transgenic mouse strains with knockouts of specific 
effector molecules Prf−/−, Tnfrsf1α(−/−), or IFNγ−/−; *P < 0.05 compared to 
all other time points, two-way ANOVA followed by Tukey’s test.
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Figure 7b displays representative  immunohistochemistry 
images of Cre recombinase and β-galactosidase from either 
 immunized or nonimmunized ROSA26 mice injected with 
Ad-CAG-Cre in the brain. Stereological quantification of 
Cre recombinase and β-galactosidase immunoreactive cells in 
the brains of ROSA26 mice reveal a significant reduction in the 
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Figure 5 elimination of Ad-mediated transgene expression upon immunization is not reversed by irradiation. C57BL/6 mice were injected with 
Ad-TK in the brain and 30 days later immunized i.p. with either Ad-HPRT or saline as control. 30 days after immunization, mice were immunosup-
pressed using irradiation. Mice were euthanized 5 days post immunosupression for further analysis. (a) Stereological quantification of TK immuno-
reactive cells in the mouse brain following irradiation treatment. *P < 0.05 compared to nonimmunized mice, one-way ANOVA followed by Tukey’s 
test. (b) Stereological quantification of CD4+ immunoreactive cells in the mouse brain following irradiation. *P < 0.05 compared to immunized 
mice, one-way ANOVA followed by Tukey’s test. Flow cytometry analysis reveals that (c) CD8+ T cells and (d) CD4+ T cells are depleted from the 
spleens of irradiated mice; *P < 0.05 compared to nonimmunized mice, one-way ANOVA followed by Tukey’s test. (e) ELISPOT analysis reveals that 
the frequency of adenovirus-specific IFNγ-secreting T lymphocyte precursors is dramatically reduced in the spleen of the irradiated mice; *P < 0.05 
compared to immunized mice, one-way ANOVA followed by Tukey’s test.
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 number of both Cre recombinase and β-galactosidase immunore-
active cells. These data demonstrate that immunization eliminates 
adenovirally transduced cells from the brain (Figure 7c). To assess 
whether Ad-transduced astrocytes and/or neurons are killed 
 following immunization, we performed double labeling  confocal 
microscopy with a neuronal marker (NeuN) or an astrocyte marker 
(GFAP) and Cre recombinase or β-galactosidase  expression in non-
immunized (Figure 7d) or immunized ROSA26 mice (Figure 7e). 
Even though both populations of transduced cells are significantly 
reduced, in the immunized animals, a higher percentage of cells 
that survived the immune attack are astrocytes.
dIscussIon
The elucidation of the cellular and molecular mechanisms by 
which the immune response clears viral gene expression from 
the brain is crucial to the safety and efficacy of clinical trials in 
 neurological gene therapy. If host defense mechanisms simply 
 abolish  transgene expression, the effectiveness of gene therapy 
will be reduced. However, if the immune response both sup-
presses transgene expression and eliminates transduced brain 
cells, the symptomatology of patients suffering from chronic 
neurodegenerative disorders that involve neuronal loss would 
worsen. Elucidating how the immune system regulates transgene 
expression in the CNS is therefore of central importance to clini-
cal neurological gene therapy,1,13,15,30,35,36 especially in view of the 
continuing use of first-generation adenoviral vectors for the treat-
ment of brain diseases, specifically brain tumors.4–9,11,12,37
Utilizing a well established mouse model of brain immune 
responses to adenoviruses, we demonstrate that T cells medi-
ate elimination of transgene expression from the brain through 
what both cytotoxic and noncytotoxic mechanisms.2,3,16–18 Kinetics 
of  infiltration of immune cells into the brain produced a num-
ber of interesting and unexpected observations. The first cells to 
infiltrate the brain were CD4+ cells, which peaked at 7 days after 
 immunization, remained high for the first month, and then slowly 
decreased to basal levels during more than 4 months. To our sur-
prise, CD8+ cells entered the brain much later, with very low levels 
of CD8+ T cells found in the brain at 30 days after immunization, 
 peaking only much later, at 2–3 months after immunization, and 
then returning to basal levels by 4 months. Macrophages/mono-
cytes increased more slowly than CD4+ T cells and achieved a clear 
peak in the CNS at 2 months after immunization. This indicates 
that at the peak of the reduction seen in transduced cells, i.e., at 30 
days after immunization, CD4+ T cells are the most abundant in the 
brain, followed by macrophages, and CD8+ T cells, a distant third. 
If numbers of T cells in the brain were to determine function, then 
CD4+ T cells would be the ones mostly responsible for the decrease 
of transduced cells. However, when we carefully examined the 
capacity of T cells to establish morphological contacts with trans-
duced target cells in the brain, we found that both CD4+ and CD8+ 
T cells did indeed establish contacts with transduced cells, but that, 
overall, these contacts were very few. Specifically, less than 10% of 
all target cells are contacted by either CD4+ or CD8+ T cells at the 
peak of reduction in the number of transgene expression, though 
up to 75% of transduced cells are contacted by macrophages. Thus, 
in spite of the known importance of immunological synapses and 
their role in mediating communication between effector T cells 
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Figure 6 elimination of Ad-mediated transgene expression upon 
immunization is not reversed by rapamycin. C57BL/6 mice were 
injected with Ad-TK in the brain and 30 days later, immunized 
i.p. with either Ad-HPRT or saline as control. 30 days after immuni-
zation, mice were immunosuppressed by treatment with rapamycin. 
Mice were euthanized 5 days post immunosupression for further anal-
ysis. (a) Stereological quantification of TK immunoreactive cells in the 
mouse brain following rapamycin treatment. *P < 0.05 compared to 
nonimmunized mice, one-way ANOVA followed by Tukey’s test. Flow 
cytometry analysis reveals that (b) CD4+ T cells and (c) CD8+ T cells 
are depleted from the spleens of rapamycin-treated mice; *P < 0.05 
compared to  nonimmunized mice, one-way ANOVA followed by 
Tukey’s test.
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and target cells in the brain,3,16,18,38–40 the low number of contacts 
detected between T cells and target cells would appear to argue that 
most of the elimination of transduced cells would indeed be exerted 
by T cells in an indirect manner likely through cytokine secretion. 
Furthermore, the contacts detected between macrophages and 
transduced cells indicated clearly that macrophages were able to 
phagocytose transduced target cells. Although our experiments do 
not allow us to determine whether macrophages do so after the fact 
that the target cell has been damaged, or do the damage themselves, 
we demonstrate that macrophages can phagocytose transduced 
cells, a fact we show for cells transduced with two different viral 
vectors and two different transgenes.
Our data conclusively show that CD4+ and CD8+ T cells 
are required to eliminate transgene expression and that expres-
sion of both IFNγ and the early expression of perforin and TNFα 
are also necessary for transgene elimination. Our results, taken 
from studies in several lines of transgenic animals, devoid of spe-
cific immune cell populations and effector molecules, show that 
there are several specific pathways at work in the elimination 
of adenoviral-mediated transgene expression from the CNS. In 
contrast, the need for the adaptive immune system and specific 
CD4+ and CD8+ T cells was demonstrated by persistent trans-
gene expression in immunodeficient Rag1(−/−) mice as well as in 
CD4(−/−), and CD8(−/−) mice. Elimination of expression of the key T 
cell cytokine effectors using IFNγ(−/−) Prf(−/−) and Tnfrsf1α(−/−) mice 
clearly implicates these cytokines in transgene expression elimi-
nation.30,35,41 Importantly, we demonstrate that neurons represent 
~80% of transduced cells, and astrocytes ~10%. As the number of 
transduced cells falls to below 10% of nonimmunized levels, these 
data strongly indicate that the majority of transduced neurons is 
indeed being lost.
The largest decrease in transgene expression is seen between 14 
and 30 days following immunization, at which time mainly CD4+ 
lymphocytes have infiltrated the brain. These data suggest that 
CD4+ T cells initiate the process of transgene elimination from the 
brain, a conclusion supported by results from animals deficient in 
CD4+ T cells. The influx of CD4+ T cells occurs simultaneously 
with an increase in F4/80+ macrophages/microglia. CD8+ T cells 
infiltrated the brain at later time points, suggesting that they are 
responsible for the late phase of transgene elimination.
Immunosuppression experiments demonstrate that persis-
tence of immune cells in the CNS is not required to inhibit viral 
gene expression, as the reduction of transgene expression was 
irreversible following either irradiation or rapamycin treatment.
The challenge of determining whether brain cells are being 
killed or whether transgene expression from vectors is being 
inhibited led us to develop a novel method to detect death of 
brain cells transduced by viral vectors. This method demon-
strates that a majority of transduced cells (>70%) is effectively 
eliminated by the immune system (i.e., loss of expression of the 
transgene encoded by the vector and the gene encoded within 
the host cell’s genome that marks the cell as having been infected 
by a recombinant  adenoviral vector expressing Cre recombinase). 
A small  population of cells remained unaffected by the immune 
response.
Further evidence of cytotoxicity comes from phagocytosis 
of transduced cells by F4/80+ labeled macrophages/microglia. 
Phagocytosis represents a late stage in the process of transduced 
cell death. The exact mechanism by which brain cells actu-
ally die remains to be determined. Detection of apoptosis using 
either immunostaining to detect activated caspase 3 or staining 
for apoptosis via Terminal dUTP nick end labeling failed to label 
transduced cells (results not shown).
In summary, our results provide strong evidence that 
 elimination of virally transduced brain cells occurs as a result 
of the  systemic immunization against adenoviral vectors. Our 
 experiments  demonstrate that CD4+ and CD8+ T cells are 
 necessary for transgene elimination and that their effects are 
mediated, at least in part, by IFNγ, perforin, and TNFα. Our data 
demonstrating that the immune system can eliminate adenovi-
rally transduced brain cells indicates that this phenomenon will 
have to be carefully studied and monitored during future clinical 
trial using adenoviral vectors, or potentially other viral vectors.
MAterIAls And Methods
Adenoviral vectors. Adenoviruses used in this study were first-generation 
E1/E3-deleted recombinant adenovirus vectors based on adenovirus type 
5. The construction of Ad-TK (expressing HSV1-TK), Ad-β-gal (express-
ing β-galactosidase), and Ad-HPRT (expressing hypoxanthine-guanine 
phosphoribosyl-transferase) has been described in detail elsewhere.42–44 
In both vectors, the transgenes are under the major immediate early 
human cytomegalovirus promoter (hCMV). All viruses tested negative 
for the presence of replication competent adenoviral vectors (RCA) and 
lipopolisacharide (LPS) as described before.45 Ad-CAG-Cre (Ad-Cre) pre-
viously described was a generous gift from Dr Saito.31
Animals, surgical procedures, viruses. C57BL/6, B6;129Gt(ROSA)26Sortm1Sho/J 
(ROSA26 mice) and transgenic knockout mice Rag1(−/−), CD4(−/−), CD8(−/−), 
IFNγ(−/−), Tnfrsf1α(−/−), and Prf1(−/−), all on C57BL/6 background, were pur-
chased from the Jackson Laboratory (Bar Harbor, ME) and housed in spe-
cific pathogen-free conditions in the Department of Comparative Medicine 
of Cedars-Sinai Medical Center. All experimental procedures were carried 
out in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals and approved by Cedars-Sinai Medical Center Institutional 
Animal Care and Use Committee (CSMC IACUC). Mice were anesthetized 
using ketamine (75 mg/kg) and medetomidine (0.5 mg/kg) and placed in 
a stereotactic apparatus modified for mice. Animals were injected into the 
right striatum (stereotactic coordinates: 0.05 mm anterior, 0.22 mm lateral 
from bregma and 0.32 mm ventral from the brain’s surface) with 1 × 107 
infectious units of adenoviral vector within 0.5 μl of volume, using a 5 μl 
Hamilton syringe. Each injection was performed over a period of 3 min-
utes, with the needle being left in place for an additional 5 minutes before 
withdrawal. Thirty days after viral vector injection into the brain, animals 
were immunized systemically (i.p. injection) with 3.28 × 108 infectious units 
(iu) of Ad-HPRT in 100 μl of saline solution. At experimental endpoints, 
mice were anesthetized via i.p. injection of an overdose of ketamine (50 mg/
kg) and xylazine (50 mg/kg) and transcardially perfused with oxygenated 
Tyrode’s solution alone (for brains to be used for molecular studies) or per-
fused-fixed with oxygenated Tyrode’s solution followed by 4% paraformal-
dehyde in phosphate buffered saline (PBS). Brain tissue was removed and 
postfixed for 48 hours before immunohistochemistry and further analysis. 
Unless indicated, experiments were performed on groups of 3–5 animals 
per group.
Immunohistochemistry and immunofluorescence. Sections of the striatum 
(50 μm) were cut into six series with a vibratome and analyzed by immunohis-
tochemistry with antibodies specific for either transgene expression (TK) or 
specific immune cells as described previously.43 Sections were then incubated 
for 4 hours with biotin-conjugated secondary antibodies, followed by 4-hour 
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Figure 7 elimination of Ad-mediated transgene expression occurs primarily through loss of transduced cells. (a) Illustration of novel reporter 
system to discriminate between loss of transduced cells and downregulation of transgene expression without loss of Ad-transduced brain cells. The 
ROSA26 transgenic mouse strain contains a STOP sequence flanked with loxP sites located upstream of the transcriptional start site of the lacZ gene. 
In these animals, genomic β-galactosidase is only expressed after Cre-recombinase-mediated excision of loxP-flanked STOP sequence (Cre-recombinase 
is provided in trans from a first-generation adenoviral vector). Downregulation of Ad-mediated transgene expression should result in loss of Cre-
recombinase expression without loss of genomic β-galactosidase expression, whereas loss of both Cre-recombinase and β-galactosidase expression 
would be the result of loss of Ad-infected brain cells. (b) ROSA26 mice were injected in the brain with Ad-Cre and immunized systemically with 
Ad-HPRT, or saline as a control, 7 days later. ROSA26 mice were euthanized 35 days later and brain sections were analyzed by immunohistochemistry 
with antibodies specific for Cre-recombinase and β-galactosidase. Representative images illustrate nuclear Cre-recombinase expression or β-galactosidase 
expression. (c) Quantitative stereological analysis of Cre-recombinase and β-galactosidase immunoreactive cells in the brains of nonimmunized and 
immunized ROSA26 transgenic mice is shown; *P < 0.05 compared to nonimmunized mice, two-way ANOVA followed by Tukey’s test. Brain sections 
from (d)  nonimmunized and (e) immunized mice were double labeled with antibodies specific for Cre-recombinase (transgene expression, green) and 
neurons (red, NeuN), or β-galactosidase (transgene-mediated genomic expression, green) and astrocytes (magenta, GFAP). Immunofluorescence was 
analyzed by confocal microscopy colocalization of transgene expression and neurons or astrocytes. The percentage of double labeled cells is shown.
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additional incubation with avidin-biotin complex (Vector Laboratories, 
Ontario, Canada). Nickel-enhanced 0.02% 3,3′-diaminobenzidine in sodium 
acetate was used as the chromogen. Finally, the sections were mounted onto gel-
atin-coated slides, dehydrated, and cover slipped using  Di-n-butylPhathalate 
in Xylene mounting media for histology (Sigma-Aldrich, St. Louis, MO). For 
immunofluorescence, 50-μm sections were treated with 0.5% citrate buffer 
(70 °C, with constant shaking) for 30 minutes to increase antigen retrieval 
and penetration of the antibodies into the tissues. Nonspecific Fc binding 
sites were blocked with 10% horse serum, and sections were incubated for 48 
hours (room temperature, constant shaking) with primary antibody diluted 
in PBS containing 1% horse serum, 0.5% Triton X-100, and 0.1% sodium 
azide. Sections were incubated for 4 hours in labeled secondary antibody and 
after PBS washes, sections were incubated with 4’,6-diamidino-2-phenylin-
dole (DAPI) solution (1:1,000) in 1× PBS for 30 minutes. After washing, sec-
tions were incubated with DAPI solution for 30 minutes to label the nuclei. 
Sections were washed, mounted using Prolong antifade reagent (Invitrogen; 
Carlsbad, California), and examined using confocal microscopy (Leica 
DMIRE2, Wetzlar, Germany). Primary antibodies included custom-made 
rabbit polyclonal anti-TK (1:10,000)46 and anti-β-gal (1:1,000)47, rabbit anti-
Cre recombinase (1:10,000; Novagen-EMD, Gibbstown, NJ), rat anti-mouse 
CD8α (1:750; clone YTS169.4, Serotec, Kidlington, UK), rat anti-mouse CD4, 
(1:750; clone kt174, Serotec), rat anti-mouse CD45, (1:1,000; clone YW62.3, 
Serotec), and rat anti-mouse F4/80 (1:100, clone Cl:A3-1; Serotec). Secondary 
antibodies included biotin-conjugated goat anti-rabbit IgG (1:800; DAKO, 
Carpinteria, CA), Texas Red–conjugated goat anti-rabbit (1:1,000) and flu-
orescein (FITC)-conjugated goat anti-rat IgG (1:1,000), both from Jackson 
ImmunoResearch Laboratories (West Grove, PA), and Alexa 488-conjugated 
goat anti-rabbit (1:1,000; Molecular Probes, Carlsbad, CA).
Quantification and stereological analysis. The optical fractionator proto-
col used for unbiased stereological cell estimation in the striatum of mice 
injected with Ad-TK was as described earlier. Striatum and external capsule 
were defined according to the Mouse Brain Atlas.48 Quantification of DAB 
or fluorescent-labeled cells in the striatum was performed by the examina-
tion of five coronal sections in series from each animal. Analysis was done 
by stereological methods using a computer-assisted image analysis system 
(Stereoinvestigator software version 5.0, Microbrightfield, Vermont) with a 
Zeiss Axioplan 2 microscope controlled by a Ludl electronic MAC 5000 XY 
stage control (Ludl Electronics Products, Hawthorne, NY) and Axioplan 
Z-axis control (Carl Zeiss, Thornwood, NY) connected to a digital camera. 
The region of interest was traced using the 1.25× objective. The number of 
cells was measured in 200 × 200 μm fields that covered the surface of the 
analyzed region. Labeled cells were counted using the 20× objective with 
55 counting frames throughout the delineated area of the striatum in each 
section via the Optical Fractionator. The thickness of each counting frame 
was 50 μm and positive cells were counted only when found to be in the 
limit of the square. Data were expressed as an absolute number of positive 
cells in each anatomical region analyzed, as described previously.
In vivo cytotoxic T lymphocyte assay. Fourteen and seven days prior to 
receiving transfer of splenocytes, recipient C57BL/6 mice were immunized 
with either saline or 3 × 108 iu of Ad-HPRT. Splenocyte donor mice were 
perfused with oxygenated Tyrode’s solution, splenocytes were isolated and 
cultured in Roswell Park Memorial Institute medium supplemented with 
10% fetal bovine serum. Splenocytes were pulsed overnight with 4 µg of 
fiber peptide (VGNKNNLGL) and 1 × 109 iu of heat-inactivated Ad-HPRT 
(multiplicity of infection = 10). Pulsed splenocytes were labeled with 2 μM 
carboxyfluorescein diacetate, succinimidyl ester (CFSE) (CFSEhi) and con-
trol nonpulsed splenocytes were incubated with 0.2 μM carboxyfluorescenin 
diacetate, succinimidyl ester (CSFE) (CFSElo). CFSEhi and CFSElo cells 
were mixed at a 1:1 ratio and 2 × 108 of total splenocytes was injected into 
immunized or nonimmunized mice by tail vein injection. Eighteen hours 
after transfer, recipient mice were perfused with oxygenated Tyrode’s solu-
tion and splenocytes were isolated and analyzed for the presence of CFSEhi 
and CFSElo populations by flow cytometry.49 Animals that exhibit cytolytic 
T cells specific for adenovirus will display a reduction in the population of 
CFSEhi target cells, which had been pulsed with adenovirus epitopes.
Quantification of cell contacts. Contacts between immune cells (CD4+, 
CD8+, or F4/80-immunoreactive cells) and TK-immunoreactive cells 
were quantified in mouse brains by confocal microscopy. The number of 
contacts was defined using a Leica DMIRE2 microscope with the 63× oil 
objective and Leica Confocal Software (Solms, Germany). A series range 
for each section was determined by setting an upper and lower thresh-
old using the Z/Y Position for Spatial Image Series setting, and confocal 
microscope settings were established and maintained by Leica and local 
technicians for optimal resolution. 0.5-μm thick confocal layers of each 
section were made by choosing a number of sections through each layer. 
In each of the  sections analyzed, regions for the quantification of cell con-
tacts were selected based on areas where immune cells and TK-expressing 
cells overlapped anatomically. Contacts were defined as areas where colo-
calization of both  markers occurs between two cells in single 0.5-μm thick 
optical sections; most contacts were present over at least two to three 
0.5-μm optical sections in the z-axis. Contacts are also illustrated as they 
appear throughout the stack of sections, e.g., side-views are shown in fig-
ures illustrating the cell to cell contacts. In each single 0.5-μm layer, the 
total number of immune cells (CD4+ or CD8+), TK-expressing cells, and 
contacts were counted with Leica Confocal Software (Solms, Germany). 
The results were expressed as (i) the percentage of immune cells contacting 
TK-immunoreactive cells, (ii) the percentage of TK-immunoreactive cells 
that had contacts, and (iii) the mean number of immune cells that contact 
each TK cell.
Immunosuppression. C57BL/6 mice were injected stereotactically with 
1 × 107 iu of Ad-TK. Mice were immunized with 3 × 108 iu of Ad-HPRT 
(i.p.) 30 days after CNS injection. Mice were then immunosuppressed using 
either irradiation or by treatment with rapamycin. For irradiation treatment, 
mice were placed in an irradiation chamber and exposed to 800 rads over 
the course of 8 minutes (100 rads/min; lethal irradiation). Mice were eutha-
nized 5 days after irradiation, as they cannot survive longer following lethal 
irradiation; spleens were kept to quantitate the levels of CD4+ and CD8+ T 
cells by flow cytometry and to assess the frequency of adenovirus-specific 
IFNγ-secreting T lymphocyte precursors by ELISPOT. Brains were per-
fused-fixed using Tyrode’s and 4% paraformaldehyde and immunohis-
tochemistry was performed using either rabbit polyclonal TK antibody for 
determining transgene expression or rat anti-CD4+ antibody to determine 
the levels of CD4+ T-cell infiltration into the brain. For immunosupression 
by rapamycin, mice were treated with 3 mg/kg rapamycin (Sigma-Aldrich) 
dissolved in 2% carboxymethylcellulose (Sigma-Aldrich) every other day for 
25 days. All animals were perfused-fixed with 4% paraformaldehyde 90 days 
after CNS injection and processed for immunohistochemistry as previously 
described.2
Flow cytometry analysis. Mice were perfused with Tyrode’s solution and 
brain tissue was removed. The area around the injection site was dis-
sected, and tissue was then diced with a razor blade before homogenizing 
in Roswell Park Memorial Institute medium (Gibco; Carlsbad, CA) using 
a glass Tenbroeck homogenizer. CNS mononuclear cells were purified 
from brain tissue by centrifugation through a Percoll gradient (Sigma-
Aldrich). Cells were counted and labeled with antibodies for analysis 
by flow cytometry. Briefly, cells were resuspended at 5 × 105 cells/ml in 
1 ml of staining buffer (0.1 mol/l PBS with 1% FBS, 0.1% sodium azide). 
Cells were centrifuged and the supernatant was discarded. The cells were 
resuspended in 100 µl staining buffer containing the antibodies described 
below and incubated for 30 minutes at 4 °C. After this incubation, the 
samples were washed in 1 ml staining buffer and analyzed by flow cytom-
etry. Cells were stained with CD3-PE, CD4-PerCP, and CD8a-FITC (BD 
Pharmingen; San Jose, CA) to identify CD4+ and CD8+ T cells. Analysis 
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of cell population was performed using Summit software (Cytomation; 
Fort Collins, CO).
ELISPOT. The frequency of IFNγ-secreting T lymphocyte precursors spe-
cific for adenovirus was assessed as described previously.50 Heat-inactivated 
adenovirus was used as a stimuli.
Statistical analysis. Data were analyzed using one-way analysis of vari-
ance followed by Tukey’s test. Transduction efficiency and recombination 
in ROSA26 cells was analyzed using T-test. The results were expressed as 
mean values ± SEM. For all tests used, P value <0.05 was considered the 
cutoff for significance.
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